ABSTRACT
Lassa virus, the etiologic agent of Lassa hemorrhagic fever, infects 100,000 to 300,000 people every year in West Africa with an overall mortality rate ranging from 1 to 2%. It was discovered in 1969 and remains a significant public health risk in endemic areas. Because airborne transmission is possible and mortality can be high under certain conditions, Lassa virus has been classified as a category A bioterrorism agent. Early diagnosis is difficult due to insidious non-specific onset and to the great genetic divergence of the virus that makes RT-PCR assays unreliable. The lack of proper diagnostic tools promotes nosocomial infection and diminishes the efficacy of treatment. Recently, numerous advances have been made in the development of both diagnostic and vaccination techniques. The purpose of this review is to present an update on that research as well as the current epidemiology of Lassa virus.
